Bayer
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bayer sits in the top decile of US sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count).
Bayer: 591 sponsored US clinical trials, 21 recruiting.
Bayer sponsors 591 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 494 completed. 172 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sunscreening Agents, with 17 trials.
Top-decile sponsor footprint
Bayer ranks in the top decile of sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
494 of 552 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
591 total, page 10 of 12
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
NCT01028755
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
NCT00984282
The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
NCT01002378
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT00867815
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
NCT00910429
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
NCT00910351
Pharmacokinetic Study Comparing Aspirin and Aspirin Granules
NCT01072604
US Cycle Control and Blood Pressure Study
NCT00920985
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
NCT00930982
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
NCT00901901
Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles
NCT00910637
Primovist / Eovist in Renally Impaired Patients
NCT00908596
US Ovulation Inhibition Study in Obese Women
NCT00873483
Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
NCT00969449
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
NCT00863746
Effect on Primary Dysmenorrhea
NCT00909857
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
NCT00863681
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
NCT00865709
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
NCT00855218
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
NCT00855465
Hepatic Impairment Study
NCT00829231
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
NCT00812175
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00810693
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
NCT00791778
RDEA119 and Sorafenib Combination Dose Escalation Study
NCT00785226
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
NCT00744939
Naproxen Sodium ER Pharmacokinetic Study
NCT00818415
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
NCT00754065
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
NCT00692770
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
NCT00748046
Naproxen Sodium Extended-Release Actual Use Study
NCT00751400
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
NCT00699751
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
NCT00720057
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
NCT00709852
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
NCT00623727
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
NCT00645788
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
NCT00622479
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
NCT00664326
Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
NCT00655629
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
NCT00623480
Single/Multiple Dose Bioavailability Trial
NCT00751556
Fast & Fed Pharmacokinetic (PK) Study
NCT00692016
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine
NCT01118273
Sorafenib Long Term Extension Program
NCT00625378
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
NCT00782470
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
NCT00571649
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
NCT00623467
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
NCT00559650
Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
NCT00610194
Sorafenib/Docetaxel Dose Escalation Trial
NCT00562523
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 130 |
| Phase 2 | 107 |
| Phase 3 | 144 |
| Phase 4 | 28 |
What is open in the Bayer pipeline
21 recruiting of 591 indexed (4% open); 494 completed (84%).
Phase mix: 172 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Sunscreening Agents (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bayer: open-pipeline peers nationwide
Peers matched on 591 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bayer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 591 trials (± recruiting share)
- Janssen Research & Development · 593 trials · 11% recruiting
- City of Hope Medical Center · 582 trials · 29% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this Bayer page
591 registered trials is a research-attention snapshot, not an endorsement of Bayer or any single study.
- 21 of Bayer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sunscreening Agents is the condition Bayer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sunscreening Agents trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bayer pipeline card: 591 registered trials from official public datasets.Report a data error.